Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Insulin prices

- PMLiVE

Eli Lilly announces 70% cut to US insulin prices while also capping out-of-pocket costs

Insulin manufacturers have come under fire recently over the cost of their insulin products

- PMLiVE

Rare Disease Day 2023 – raising awareness around the world

Around one in 17 people will be affected by a rare disease at some point in their lives

- PMLiVE

Sanofi reports positive new data for multiple sclerosis treatment tolebrutinib

It is estimated that there are over 130,000 people living with the condition in the UK alone

- PMLiVE

Sanofi and Sobi’s once-weekly haemophilia A treatment approved by FDA

Current factor VIII therapies usually require patients to receive treatment every two days

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus shows consistent protection against RSV disease in infants

RSV is the most common cause of infant respiratory infections, including pneumonia

- PMLiVE

Sanofi’s enzyme replacement therapy available on NHS to Pompe disease patients

The rare genetic disorder affects around one in every 40,000 people in the UK

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis

This makes Dupixent the first and only targeted medicine indicated for this condition

- PMLiVE

Sanofi/Regeneron’s Dupixent recommended by CHMP for atopic dermatitis in children

If approved, the medicine would be the first and only targeted option in the EU for this age group

- PMLiVE

Eli Lilly announces $450m investment in US manufacturing site

In December 2022 increased demand resulted in a short supply of two of its diabetes drugs

- PMLiVE

Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval

The FDA said there was not enough trial data from patients who were treated for at least a year

- PMLiVE

AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement

Both companies will now come under the scheme imposed by the government through law

- PMLiVE

Novo Nordisk’s type 2 diabetes drug approved by FDA as first-line option

Rybelsus was initially approved in 2019 as a second-line treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links